Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Associated Retina Consultants

Neither a doctor nor a teaching hospital

Research payments

$472,183

23 payments

Through program year 2022, Associated Retina Consultants is reported as receiving $472,183 in research payments, across 23 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $66,007 7
2021 Research $180,905 5
2020 Research $170,272 5
2019 Research $54,998 6

Breakdown

Who paid Research payments · program years 2019–2022
  1. Novartis Pharmaceuticals Corporation $381,659 16 payments
  2. Amgen Inc. $30,420 2 payments
  3. Biogen, Inc. $26,022 1 payment
  4. Genentech, Inc. $24,367 1 payment
  5. Regeneron Pharmaceuticals, Inc. $8,975 1 payment
  6. Allergan Inc. $740 2 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $116,108 4 payments
  2. An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusion (Raptor) $90,677 1 payment
  3. An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusi $73,905 3 payments
  4. A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due to MacUlar Edema (Me) Secondary to Central Retinal Vein Occlusion (Crvo) $52,560 4 payments
  5. A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $47,369 3 payments
  6. ABP 938 Global P3 Study $30,420 2 payments
  7. Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS) $26,022 1 payment
  8. Port Delivery System for Ranibizumab $24,367 1 payment
  9. A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $8,975 1 payment
  10. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $1,040 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record